Treatment
Cell clinical trials
We’re tracking 5,684 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06612268RecruitingPhase 3
Testing etavopivat for sickle cell disease
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
Birmingham, AlabamaAges 12 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05733715RecruitingEarly Phase 1
Testing pembrolizumab plus lenvatinib before kidney cancer surgery
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07251582RecruitingPhase 3
Comparing infusion timing for lung cancer immunotherapy before surgery
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Changsha, HunanAges 18–75 - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Tucson, ArizonaAges 18 years+ - NCT06801834RecruitingPhase 3
Study of sacituzumab govitecan vs. standard care for advanced small cell lung cancer
This trial tests a new drug called sacituzumab govitecan against the usual treatments for people with extensive-stage small cell lung cancer that has gotten worse after initial chemotherapy. It aims to see if the new drug helps patients live longer or have better outcomes.
Anchorage, AlaskaAges 18 years+ - NCT07754890RecruitingPhase 1/Phase 2
Study of two drugs for advanced skin lymphoma
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06725550Recruiting
Acupuncture for pain in sickle cell disease
This trial tests whether adding acupuncture to standard pain treatments can help manage pain in people with sickle cell disease. It involves brain scans, questionnaires, and acupuncture sessions to see if this approach reduces pain and improves quality of life.
Cincinnati, OhioAges 14–80 - NCT05099172RecruitingPhase 1/Phase 2
Study drug for EGFR or HER2-mutated advanced lung cancer
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Gilbert, ArizonaAges 18 years+ - NCT02688894Recruiting
Molecular testing for relapsed small cell lung cancer
This study uses tumor tissue to look for molecular (biologic) changes after your small cell lung cancer comes back. It may help doctors choose the most appropriate next treatment based on what the cancer’s biology shows.
IncheonAges 20 years+ - NCT06915038Recruiting
Measuring tumor DNA in blood for HPV-positive throat cancer
This study looks at a blood test that finds DNA from HPV-related throat tumors. It may help doctors decide on surgery and check if the cancer is completely removed.
Carmel, IndianaAges 18 years+ - NCT02015013RecruitingPhase 2
Blood cell collection study for immune system disorders
This study collects blood-forming cells from people with low CD4 counts and healthy volunteers to learn how the immune system works. It may help researchers better understand and treat conditions like idiopathic CD4 lymphocytopenia.
Bethesda, MarylandAges 18–65 - NCT06236139RecruitingPhase 1/Phase 2
Immune cells plus hormone therapy for advanced prostate cancer
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
Seattle, WashingtonAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT05544526RecruitingPhase 1
CAR T cell treatment for brainstem spinal cord tumor in children
This Phase 1 trial tests CAR T cells designed to attack a specific target (GD2) on a rare childhood brain/spinal tumor called DMG with a certain gene change (H3K27M). It is mainly designed to check safety and early signs of effectiveness after prior treatments.
LondonAges Up to 16 years - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Goodyear, ArizonaAges 18 years+ - NCT03391778Enrolling by invitationPhase 1
Long-term follow-up for cell therapy participants
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
Atlanta, GeorgiaAges Any age - NCT06596954Recruiting
Lymphocyte-sparing radiation for esophageal cancer
This trial tests a special type of radiation therapy that aims to spare your immune cells (lymphocytes) while treating esophageal cancer. It may help patients with locally advanced esophageal squamous cell carcinoma who are in good overall health.
Shanghai, ChinaAges 18–80 - NCT07239596RecruitingPhase 1/Phase 2
Study of three drugs for advanced kidney cancer
This trial tests a combination of three drugs (SHR-8068, adebrelimab, and another anti-tumor drug) for people with advanced kidney cancer (clear cell type). The goal is to see if the combination works better than current treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Atlanta, GeorgiaAges 50 years+ - NCT04253964RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced lung cancer
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
Winston-Salem, North CarolinaAges 18 years+ - NCT07541170RecruitingPhase 3
Testing divarasib after lung cancer surgery and chemotherapy
This study tests whether a drug called divarasib can help prevent lung cancer from coming back after surgery and initial treatment. You would only qualify if your cancer has a specific genetic mutation (KRAS G12C) and you've already had surgery and chemotherapy with immunotherapy.
Clovis, CaliforniaAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Daphne, AlabamaAges 18 years+ - NCT07668752RecruitingPhase 3
New pill (GFH375) vs chemo for KRAS G12D lung cancer
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
Shanghai, Shanghai MunicipalityAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,684 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.